Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciclesonide Nasal Spray in Perennial Allergic Rhinitis
NCT00659750Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2003
- Primary completion
- May 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in perennial allergic rhinitis (PAR) comparing Ciclesonide 200µg with Placebo (2 arms). Primary endpoint: Total Nasal Symptom Score at 6 weeks. Started Dec 2003; status: completed.
02
Drugs
ciclesonide
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00659750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00659750.